High-Grade Glioma - Pipeline Review, H2 2015 Is

Released
High-Grade Glioma - Pipeline Review, H2 2015 Summary Global Markets Direct s, High-Grade Glioma Pipeline Review, H2 2015 , provides an overview of the High-Grade Glioma s therapeutic pipeline. This
report provides comprehensive information on the therapeutic development for High-Grade Glioma,
complete with comparative analysis at various stages, therapeutics assessment by drug target,
mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates,
and featured news and press releases. It also reviews key players involved in the therapeutic
development for High-Grade Glioma and special features on late-stage and discontinued projects. Global
Markets Directs report features investigational drugs from across globe covering over 20 therapy areas
and nearly 3,000 indications. The report is built using data and information sourced from Global Markets
Directs proprietary databases, Company/University websites, SEC filings, investor presentations and
featured press releases from company/university sites and industry-specific third party sources, put
together by Global Markets Direct s team. Drug profiles/records featured in the report undergoes
periodic updation following a stringent set of processes that ensures that all the profiles are updated
with the latest set of information. Additionally, processes including live news & deals tracking, browser
based alert-box and clinical trials registries tracking ensure that the most recent developments are
captured on a real time basis. The report enhances decision making capabilities and help to create
effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying
new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the
report may be removed or altered based on the availability and relevance of data for the indicated
disease. Scope - The report provides a snapshot of the global therapeutic landscape of High-Grade
Glioma - The report reviews key pipeline products under drug profile section which includes, product
description, MoA and R&D brief, licensing and collaboration details & other developmental activities The report reviews key players involved in the therapeutics development for High-Grade Glioma and
enlists all their major and minor projects - The report summarizes all the dormant and discontinued
pipeline projects - A review of the High-Grade Glioma products under development by companies and
universities/research institutes based on information derived from company and industry-specific
sources - Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages - A detailed assessment of monotherapy and
combination therapy pipeline projects - Coverage of the High-Grade Glioma pipeline on the basis of
target, MoA, route of administration and molecule type - Latest news and deals relating related to
pipeline products Reasons to buy - Provides strategically significant competitor information, analysis,
and insights to formulate effective R&D development strategies - Identify emerging players with
potentially strong product portfolio and create effective counter-strategies to gain competitive
advantage - Develop strategic initiatives by understanding the focus areas of leading companies Identify and understand important and diverse types of therapeutics under development for High-Grade
Glioma - Plan mergers and acquisitions effectively by identifying key players of the most promising
pipeline - Devise corrective measures for pipeline projects by understanding High-Grade Glioma pipeline
depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies
by identifying prospective partners with the most attractive projects to enhance and expand business

potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and
understanding the factors that drove them from pipeline
with TOC @ http://www.idatainsights.com/reports-landing-page.php?id=173382/high-gradeglioma-pipeline-review-h2-2015

Browse

To Get Sample Copy of Report visit @ http://www.idatainsights.com/reports-landingpage.php?id=173382/high-grade-glioma-pipeline-review-h2-2015

Table of Contents

Introduction 8
Global Markets Direct Report Coverage 8
High-Grade Glioma Overview 9
Therapeutics Development 10
Pipeline Products for High-Grade Glioma - Overview 10
Pipeline Products for High-Grade Glioma - Comparative Analysis 11
High-Grade Glioma - Therapeutics under Development by Companies 12
High-Grade Glioma - Therapeutics under Investigation by Universities/Institutes 14
High-Grade Glioma - Pipeline Products Glance 15
Clinical Stage Products 15
Early Stage Products 16
High-Grade Glioma - Products under Development by Companies 17
High-Grade Glioma - Products under Investigation by Universities/Institutes 18
High-Grade Glioma - Companies Involved in Therapeutics Development 19
AngioChem Inc. 19
Arog Pharmaceuticals, Inc. 20
Bayer AG 21
Boehringer Ingelheim GmbH 22
Cavion LLC 23
Kinex Pharmaceuticals, LLC 24
2

Merrimack Pharmaceuticals, Inc. 25

Millennium Pharmaceuticals, Inc. 26
Nektar Therapeutics 27
Novartis AG 28
Oncolytics Biotech Inc. 29
Sanofi 30
Stemline Therapeutics, Inc. 31
Targepeutics, Inc. 32
Tocagen Inc. 33
Virttu Biologics Limited 34
High-Grade Glioma - Therapeutics Assessment 35
Assessment by Monotherapy Products 35
Assessment by Combination Products 36
Assessment by Target 37
Assessment by Mechanism of Action 39
Assessment by Route of Administration 41
Assessment by Molecule Type 43
Drug Profiles 45
(dabrafenib mesylate + trametinib dimethyl sulfoxide) - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
alisertib - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
crenolanib besylate - Drug Profile 51
3

Product Description 51
Mechanism of Action 51
R&D Progress 51
Dendritic Cell Therapy for Gliomas - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Dendritic Cell Therapy for Oncology - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Dendritic Cell Therapy to Target MAGE-A1, MAGE-A3 and NY-ESO-1 for Oncology - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
dianhydrogalactitol - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
etirinotecan pegol - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
flucytosine + TBio-01 - Drug Profile 61
Product Description 61
Mechanism of Action 61

R&D Progress 61
GB-13 - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
Gene Therapy for High-Grade Glioma and Liver Transplantation - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
HSV-1716 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
irinotecan hydrochloride - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
irinotecan hydrochloride + TBio-02 - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
KX-02 - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
mibefradil dihydrochloride - Drug Profile 74
Product Description 74
5

Mechanism of Action 74
R&D Progress 74
nintedanib - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
paclitaxel trevatide - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
pelareorep - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
plerixafor - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
SL-701 - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
sorafenib tosylate - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92

Toca-Gamma - Drug Profile 96

Product Description 96
Mechanism of Action 96
R&D Progress 96
Toca-RNAi - Drug Profile 97
Product Description 97
Mechanism of Action 97
R&D Progress 97
vocimagene amiretrorepvec + flucytosine ER - Drug Profile 98
Product Description 98
Mechanism of Action 98
R&D Progress 98
High-Grade Glioma - Recent Pipeline Updates 100
High-Grade Glioma - Dormant Projects 153
High-Grade Glioma - Discontinued Products 154
High-Grade Glioma - Product Development Milestones 155
Featured News & Press Releases 155
Jun 01, 2015: Merrimack Pharmaceuticals Announces Data from an Investigator-Sponsored Phase 1
Study Showing Acceptable Safety Profile for MM-398 in High-Grade Glioma 155
May 28, 2015: Cavion to Present Clinical Trial Data at ASCO 156
May 31, 2014: Positive Data from Phase 2 Trial of NKTR-102 in Patients with Avastin?-Refractory HighGrade Glioma Presented at 50th ASCO Meeting 156
Appendix 158
Methodology 158
Coverage 158
Secondary Research 158
Primary Research 158
Expert Panel Validation 158
7

Contact Us 158
Disclaimer 159

Read More
http://www.idatainsights.com/reports-landing-page.php?id=173382/high-grade-gliomapipeline-review-h2-2015
About Us:
iData Insights which operates under Precision Research and Consulting Private Limited is a leading
market research information aggregator and marketing research consulting firm. We conduct both
primary and secondary research. Our work does not end with research it is also involved in distributing
reports for different companies . We provide actionable recommendations and provide our expertise for
business success today and tomorrow. It is our goal to be a partner to our clients in the exploration and
discovery, and then be their guide in the implementation of changes that will make a difference to their
bottom line.
ContactUs:
iData Insights
Tel: 1-866-237-2965
Web: http://www.idatainsights.com
Email: info@idatainsights.com
About iData Insights
We work around the clock until our clients are completely satisfied with their promised results. It is our
mission to provide timely services coupled with acute client care to create a long-lasting relationship
with you. We deliver on our promise to provide results that are essential to the success of your
company. We believe that by doing so, we will earn the trust of our clients for future projects